Oric PharmaceuticalsORIC
ORIC
About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Employees: 122
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
196% more call options, than puts
Call options by funds: $74K | Put options by funds: $25K
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
26% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 39
11% more funds holding
Funds holding: 129 [Q4 2024] → 143 (+14) [Q1 2025]
4.11% more ownership
Funds ownership: 107.4% [Q4 2024] → 111.52% (+4.11%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 5 (+0) [Q1 2025]
28% less capital invested
Capital invested by funds: $612M [Q4 2024] → $442M (-$170M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
25%
upside
Avg. target
$17
77%
upside
High target
$22
128%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns | 128%upside $22 | Buy Maintained | 9 May 2025 |
Oppenheimer Matthew Biegler | 25%upside $12 | Outperform Maintained | 6 May 2025 |
Financial journalist opinion
Based on 9 articles about ORIC published over the past 30 days
Positive
Zacks Investment Research
1 day ago
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
GlobeNewsWire
1 week ago
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.
Positive
Zacks Investment Research
1 week ago
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
2 weeks ago
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
Positive
Benzinga
2 weeks ago
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
ORIC Pharmaceuticals Inc. ORIC released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).
Neutral
GlobeNewsWire
2 weeks ago
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital
Neutral
GlobeNewsWire
2 weeks ago
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated primary endpoint readout from first Phase 3 trial SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced potentially best-in-class preliminary efficacy and safety data from the ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).
Neutral
GlobeNewsWire
2 weeks ago
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June:
Neutral
GlobeNewsWire
2 weeks ago
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m.
Neutral
GlobeNewsWire
1 month ago
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones
Charts implemented using Lightweight Charts™